Nicox has repaid all secured debt owed to Kreos Capital and secured up to €4 million in new unsecured...

Mesoblast has reshaped its board as it transitions from development to commercialization, appointing Philip Facchina as non-executive chair and...

Mesoblast has reshaped its board as it pivots from development to commercial execution following its first FDA approval and...

Zealand Pharma has set a 2030 agenda to become a next‑generation metabolic health leader, targeting five product launches, more...

Nasus Pharma has moved its intranasal epinephrine program, NS002, into a Health Canada–authorized Phase 2 study, has dosed the...

Intelligent Bio Solutions has struck a strategic manufacturing partnership with Syrma Johari Medtech to scale production of its intelligent...

Arvinas has secured FDA acceptance of the NDA for vepdegestrant, its oral PROTAC estrogen receptor degrader for ESR1‑mutated ER+/HER2‑...

Moonlake Immunotherapeutics reported third-quarter 2025 results, with $380.5 million in cash and committed debt, extending the runway into the...

EyePoint Pharmaceuticals has fully enrolled its two Phase 3 wet AMD trials, LUGANO and LUCIA, with more than 900...

Centessa Pharmaceuticals reported positive initial Phase 2a results for ORX750, its oral OX2R agonist, across narcolepsy type 1, narcolepsy...